TARGET PharmaSolutions: Novartis enters into alliance for TARGET-NASH

Target PharmaSolutions asserts that Novartis has entered into strategic alliance for TARGET-NASH.

TARGET-NASH is a longitudinal observational study that assesses adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH will enroll up to 15,000 patients over the coming years.

Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated, “We are very excited to have Novartis join TARGET-NASH. TARGET-NASH has enrolled a large, diverse patient population and is generating valuable real-world data and insight on NASH, including the natural history of the disease and current treatment patterns.  The TARGET real-world data solution which includes a biorepository and patient reported outcomes is a critical resource for our collaborators as they work to better understand and to combat this rapidly growing disease.”

TARGET PharmaSolutions  assures improvement of Clinical, Medical and Commercial results . The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes thereby providing a comprehensive and inclusive all-round analysis.